# A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study

> **NCT07044765** · PHASE1 · NOT_YET_RECRUITING · sponsor: **AJU Pharm Co., Ltd.** · enrollment: 32 (estimated)

## Conditions studied

- Type2 Diabetes Mellitus

## Interventions

- **DRUG:** Comparator 1
- **DRUG:** Comparator 2
- **DRUG:** Test Drug

## Key facts

- **NCT ID:** NCT07044765
- **Lead sponsor:** AJU Pharm Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2025-11
- **Final completion:** 2025-11
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07044765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07044765, "A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07044765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*